751 related articles for article (PubMed ID: 25970749)
1. Frequent epigenetic suppression of tumor suppressor gene glutathione peroxidase 3 by promoter hypermethylation and its clinical implication in clear cell renal cell carcinoma.
Liu Q; Jin J; Ying J; Sun M; Cui Y; Zhang L; Xu B; Fan Y; Zhang Q
Int J Mol Sci; 2015 May; 16(5):10636-49. PubMed ID: 25970749
[TBL] [Abstract][Full Text] [Related]
2. Hypermethylation of the 16q23.1 tumor suppressor gene ADAMTS18 in clear cell renal cell carcinoma.
Xu B; Zhang L; Luo C; Qi Y; Cui Y; Ying JM; Zhang Q; Jin J
Int J Mol Sci; 2015 Jan; 16(1):1051-65. PubMed ID: 25569086
[TBL] [Abstract][Full Text] [Related]
3. Downregulation of CLDN7 due to promoter hypermethylation is associated with human clear cell renal cell carcinoma progression and poor prognosis.
Li Y; Gong Y; Ning X; Peng D; Liu L; He S; Gong K; Zhang C; Li X; Zhou L
J Exp Clin Cancer Res; 2018 Nov; 37(1):276. PubMed ID: 30428910
[TBL] [Abstract][Full Text] [Related]
4. Aberrant promoter methylation of DLEC1, a critical 3p22 tumor suppressor for renal cell carcinoma, is associated with more advanced tumor stage.
Zhang Q; Ying J; Li J; Fan Y; Poon FF; Ng KM; Tao Q; Jin J
J Urol; 2010 Aug; 184(2):731-7. PubMed ID: 20639048
[TBL] [Abstract][Full Text] [Related]
5. Protocadherin17 Promoter Methylation is a Potential Predictive Biomarker in Clear Cell Renal Cell Carcinoma.
Lin YL; Gui SL; Guo H; Ma JG; Li WP
Med Sci Monit; 2015 Sep; 21():2870-6. PubMed ID: 26404644
[TBL] [Abstract][Full Text] [Related]
6. Epigenetic inactivation of the RASSF1A 3p21.3 tumor suppressor gene in both clear cell and papillary renal cell carcinoma.
Morrissey C; Martinez A; Zatyka M; Agathanggelou A; Honorio S; Astuti D; Morgan NV; Moch H; Richards FM; Kishida T; Yao M; Schraml P; Latif F; Maher ER
Cancer Res; 2001 Oct; 61(19):7277-81. PubMed ID: 11585766
[TBL] [Abstract][Full Text] [Related]
7. Identification of GPX3 epigenetically silenced by CpG methylation in human esophageal squamous cell carcinoma.
He Y; Wang Y; Li P; Zhu S; Wang J; Zhang S
Dig Dis Sci; 2011 Mar; 56(3):681-8. PubMed ID: 20725785
[TBL] [Abstract][Full Text] [Related]
8. [Suppression of NR0B2 gene in Clear Cell Renal Cell Carcinoma Is Associated with Hypermethylation of Its Promoter].
Kudryavtseva AV; Nyushko KM; Zaretsky AR; Shagin DA; Sadritdinova AF; Fedorova MS; Savvateeva MV; Guvatova ZG; Pudova EA; Alekseev BY; Dmitriev AA; Snezhkina AV
Mol Biol (Mosk); 2018; 52(3):482-488. PubMed ID: 29989580
[TBL] [Abstract][Full Text] [Related]
9. Promoter methylation inhibits expression of tumor suppressor KIBRA in human clear cell renal cell carcinoma.
Schelleckes K; Schmitz B; Ciarimboli G; Lenders M; Pavenstädt HJ; Herrmann E; Brand SM; Brand E
Clin Epigenetics; 2017; 9():109. PubMed ID: 29046731
[TBL] [Abstract][Full Text] [Related]
10. Genetic and epigenetic control of UNC5C expression in human renal cell carcinoma.
Lv D; Zhao W; Dong D; Qian XP; Zhang Y; Tian XJ; Zhang J
Eur J Cancer; 2011 Sep; 47(13):2068-76. PubMed ID: 21600761
[TBL] [Abstract][Full Text] [Related]
11. Epigenetic inactivation of HOXA11, a novel functional tumor suppressor for renal cell carcinoma, is associated with RCC TNM classification.
Wang L; Cui Y; Sheng J; Yang Y; Kuang G; Fan Y; Jin J; Zhang Q
Oncotarget; 2017 Mar; 8(13):21861-21870. PubMed ID: 28423531
[TBL] [Abstract][Full Text] [Related]
12. Keap1/Nrf2 pathway in kidney cancer: frequent methylation of KEAP1 gene promoter in clear renal cell carcinoma.
Fabrizio FP; Costantini M; Copetti M; la Torre A; Sparaneo A; Fontana A; Poeta L; Gallucci M; Sentinelli S; Graziano P; Parente P; Pompeo V; De Salvo L; Simone G; Papalia R; Picardo F; Balsamo T; Flammia GP; Trombetta D; Pantalone A; Kok K; Paranita F; Muscarella LA; Fazio VM
Oncotarget; 2017 Feb; 8(7):11187-11198. PubMed ID: 28061437
[TBL] [Abstract][Full Text] [Related]
13. Epigenetic inactivation of hydroxymethylglutaryl CoA synthase reduces ketogenesis and facilitates tumor cell motility in clear cell renal carcinoma.
Han P; Wang Y; Luo W; Lu Y; Zhou X; Yang Y; Zheng Q; Li D; Wu S; Li L; Zhang H; Zhao J; Zhang Z; Matskova L; Li P; Zhou X
Pathol Res Pract; 2021 Nov; 227():153622. PubMed ID: 34624592
[TBL] [Abstract][Full Text] [Related]
14.
Su X; Zhang J; Mouawad R; Compérat E; Rouprêt M; Allanic F; Parra J; Bitker MO; Thompson EJ; Gowrishankar B; Houldsworth J; Weinstein JN; Tost J; Broom BM; Khayat D; Spano JP; Tannir NM; Malouf GG
Cancer Res; 2017 Sep; 77(18):4835-4845. PubMed ID: 28754676
[TBL] [Abstract][Full Text] [Related]
15. Tumor suppressor activity and epigenetic inactivation of hepatocyte growth factor activator inhibitor type 2/SPINT2 in papillary and clear cell renal cell carcinoma.
Morris MR; Gentle D; Abdulrahman M; Maina EN; Gupta K; Banks RE; Wiesener MS; Kishida T; Yao M; Teh B; Latif F; Maher ER
Cancer Res; 2005 Jun; 65(11):4598-606. PubMed ID: 15930277
[TBL] [Abstract][Full Text] [Related]
16. The epigenetic modifier CHD5 functions as a novel tumor suppressor for renal cell carcinoma and is predominantly inactivated by promoter CpG methylation.
Du Z; Li L; Huang X; Jin J; Huang S; Zhang Q; Tao Q
Oncotarget; 2016 Apr; 7(16):21618-30. PubMed ID: 26943038
[TBL] [Abstract][Full Text] [Related]
17. Decreased expression of RASSF1A tumor suppressor gene is associated with worse prognosis in clear cell renal cell carcinoma.
Klacz J; Wierzbicki PM; Wronska A; Rybarczyk A; Stanislawowski M; Slebioda T; Olejniczak A; Matuszewski M; Kmiec Z
Int J Oncol; 2016 Jan; 48(1):55-66. PubMed ID: 26648328
[TBL] [Abstract][Full Text] [Related]
18. Epigenetic silencing of ASPP1 confers 5-FU resistance in clear cell renal cell carcinoma by preventing p53 activation.
Wang X; Cheng Y; Zhu Y; Li H; Ge W; Wu X; Zhao K; Yuan J; Li Z; Jiang S; Han Z; Jiang Q; Wu Q; Liu T; Zhang C; Yu M; Hu Y
Int J Cancer; 2017 Oct; 141(7):1422-1433. PubMed ID: 28656647
[TBL] [Abstract][Full Text] [Related]
19. Aberrant Methylation of the 1p36 Tumor Suppressor Gene RIZ1 in Renal Cell Carcinoma.
Ge P; Yu X; Wang ZC; Lin J
Asian Pac J Cancer Prev; 2015; 16(9):4071-5. PubMed ID: 25987089
[TBL] [Abstract][Full Text] [Related]
20. DNA methylation of the SLC16A3 promoter regulates expression of the human lactate transporter MCT4 in renal cancer with consequences for clinical outcome.
Fisel P; Kruck S; Winter S; Bedke J; Hennenlotter J; Nies AT; Scharpf M; Fend F; Stenzl A; Schwab M; Schaeffeler E
Clin Cancer Res; 2013 Sep; 19(18):5170-81. PubMed ID: 23881922
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]